Therapeutic potential and the mechanism of action of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in established Experimental Autoimmune Myasthenia Gravis (128.13)

JIAN RONG SHENG,Bellur S Prabhakar,Matthew N Meriggioli

DOI: https://doi.org/10.4049/jimmunol.178.supp.128.13

2007-04-01

The Journal of Immunology

Abstract:Abstract Dendritic cells (DCs) are potent antigen presenting cells responsible for priming naïve T cells in an immune response. Distinct subpopulations of DCs play a central role in immune regulation by preferentially inducing immunity or tolerance. Recently, we observed that the selective activation of particular subsets of DCs utilizing fms-like tyrosine kinase receptor 3 ligand (Flt3-L) and granulocyte-macrophage colony-stimulating factor (GM-CSF) had profound effects on the induction of Experimental Autoimmune Myasthenia Gravis (EAMG). Treatment with GM-CSF effectively suppressed the induction of EAMG, and down-modulated anti-AChR T cell and antibody responses. These effects were associated with the activation of CD8α- DCs, the enhanced production of suppressive cytokines such as IL-4 and IL-10, and the mobilization of CD4+CD25+ and Foxp3+ regulatory T cells (Tregs). Based on these observations, we hypothesized that the selective activation of DC subsets using GM-CSF can skew ongoing anti-AChR immune responses in favor of a Th2 polarization and mobilize antigen-specific CD4+CD25+ and Foxp3+ Tregs capable of suppressing established EAMG. In the present study, we evaluated the therapeutic potential of GM-CSF by examining its effectiveness in the treatment of established disease, and its ability to suppress ongoing autoimmune responses in active EAMG. We are continuing to understand the mechanisms of Treg induction and modes of action in the GM-CSF induced suppression of ongoing EAMG, with regard to antigen specificity and duration of induced tolerance.

immunology